Table 3 Risk factor characteristics of patients within the included studies
Study ID | Bragança et al., 2021 | Ross et al., 2020 | Pelland-Marcotte et al., 2019 | Belsky et al., 2019 | Akam-Venkata et al., 2018 | Ji et al., 2019 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sample size | 29 | 33 | 170 | 8 | 9 | 9 | |||||||||
Exposure group | NMPE | SMPE | MPE | SMPE | MPE | NMPE | SMPE + MPE | SMPE | Total (SMPE + MPE) | SMPE | MPE | Total (SMPE + MPE) | SMPE | MPE | |
n (%) | 13 | 11 | 5 | 24 | 9 | 121 | 49 | 5 | 9 | 6 | 3 | 9 | 4 | 5 | |
Risk factors n (%) | OCP | - | - | - | 15 (88) | 1 (20) | - | - | 1 (16%) | 4 (67%) | 2 (33%) | 2 (66%) | 3 (33%) | - | - |
Obesity | - | - | - | 9(38) | 2(22) | 25 (21%) | 10 (20%) | 1 (16%) | 6 (67%) | 3 (33%) | - | - | |||
Cardiac disease | - | - | - | 0 | 2(22) | 17 (14%) | 16 (33%) | - | - | - | - | - | - | - | |
Central venous catheter | - | - | - | 4(17) | 6(67) | 48 (40%) | 29 (59%) | 1 (16%) | - | - | - | - | - | - | |
Immobility | - | - | - | 3(13) | 6(67) | - | - | - | 5 (56%) | 2 (33%) | 3 (100%) | ||||
Malignancy | - | - | - | 1 (4) | 2 (22) | 28 (23%) | 5 (10%) | - | - | - | - | - | - | - | |
Family history of VTE | - | - | - | 8 (36) | 0 | 30 (25%) | 7 (14%) | - | - | - | - | - | - | - | |
History of VTE | - | - | - | 0 | 2 (22) | 21 (17%) | 14 (29%) | - | - | - | - | - | - | - | |
Postoperative | - | - | - | 1(4) | 4(44) | 12 (10%) | 4 (8%) | - | - | - | - | - | - | - | |
Vascular malformation | - | - | - | 2 (8) | 2 (22) | 7 (6%) | 6 (12%) | - | - | - | - | - | - | - | |
Critical illness | - | - | - | 2(8) | 5(56) | - | - | - | - | - | - | - | - | - | |
Infectious or inflammatory | - | - | - | - | - | 22 (18%) | 8 (16%) | - | - | - | - | - | - | - | |
Psychiatric medications | - | - | - | 7 (29) | 1 (11) | - | - | - | - | - | - | - | - | - | |
Pulmonary disease | - | - | - | 1 (4) | 2 (22) | - | - | 1 (16%) | - | - | - | - | - | - | |
Prothrombotic disorder | - | - | - | 7 (39) | 1 (100) | - | - | - | - | - | - | - | - | - | |
SLE | - | - | - | - | - | - | - | 2 (23%) | |||||||
haematological diseases | - | - | - | - | - | - | - | - | 3 (33%) | - | - | - | - | - | |